Thanks to ample customer demand, production increases, and an improving global supply chain for drug transport and delivery, the worldwide diabetes and weight loss drug market is expected to grow to $150 billion by 2032, according to BMO Capital Markets.
The U.S. Centers for Disease Control and Prevention reports that 2 in 5 U.S. adults have obesity. The numbers are sobering: 41.9% of U.S. adults are considered obese, and 9.2% are considered highly obese. Many studies also point to the direct link between obesity and serious diseases like diabetes, heart disease, and cancer.
So far, the results from weight loss drugs are promising for overweight Americans. That’s also good news for sector stocks, as companies are cleaning up with their obesity-fighting drugs. How are those stocks and others in the industry faring in 2024? Here’s an inside look…
This post originally appeared U.S. News & World Report.